SCHEMBL99627

SCHEMBL99627

O=C(O)C=Cc1ccc(-c2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
PLA2G4A P47712 1/20 0.52
ALDH1A1 P00352 5/20 0.50
LMNA P02545 3/20 0.50
HPGD P15428 2/20 0.50
MAPK1 P28482 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
DBH P09172 1/20 0.47
POLB P06746 2/20 0.46
HDAC3 O15379 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC2 Q92769 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99626 1.00 MAPT (0.54) MAPTPLA2G4AALDH1A1LMNAHPGD
SCHEMBL18290897 0.85 IP6K1 (0.49) MAPTALDH1A1LMNAHPGDMAPK1
SCHEMBL2184446 0.84 ALDH1A1 (0.60) MAPTPLA2G4AALDH1A1MAPK1TDP1
SCHEMBL11823879 0.84 ALDH1A1 (0.60) MAPTPLA2G4AALDH1A1MAPK1TDP1
SCHEMBL98673 0.82 ALDH1A1 (0.46) MAPTALDH1A1LMNAHPGDMAPK1
SCHEMBL98674 0.82 ALDH1A1 (0.46) MAPTALDH1A1LMNAHPGDMAPK1
Propionic Acid SCHEMBL27571370 0.81 PLA2G4A (0.57) MAPTPLA2G4AALDH1A1LMNAHPGD
SCHEMBL2571222 0.80 ALDH1A1 (0.58) MAPTALDH1A1LMNAHPGDTDP1
SCHEMBL2785445 0.79 ALDH5A1 (0.63) MAPTPLA2G4AALDH1A1LMNAHPGD
SCHEMBL2785447 0.79 ALDH5A1 (0.63) MAPTPLA2G4AALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2934594-B1 CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . ALMIRALL SA (ES) 2019-09-04 EP disclosed
US-20150329535-A1 NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY ALMIRALL, S.A. (ES) 2015-11-19 US disclosed
EP-2934594-A1 NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY Almirall, S.A. (ES) 2015-10-28 EP disclosed
US-9072734-B2 Quaternary ammonium salt compounds TEIJIN PHARMA LIMITED (JP) 2015-07-07 US disclosed
WO-2014095920-A1 NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY ALMIRALL, S.A. (ES) 2014-06-26 WO disclosed
EP-2426121-A1 QUATERNARY AMMONIUM SALT COMPOUND Teijin Pharma Limited (JP) 2012-03-07 EP disclosed
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS TEIJIN PHARMA LIMITED (JP) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046467-A1 QUATERNARY AMMONIUM SALT COMPOUNDS ADRB2, AGTR2, ADRB3 MAPT 2879/4885PLA2G4A 3186/4885ALDH1A1 1896/4885
US-20150329535-A1 NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY CHRM3, CHRM2, ADRB2 MAPT 2578/4885PLA2G4A 1863/4885ALDH1A1 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.